- Home
- CBUS
CBUS
Cibus Inc.
as 04-23-2025 1:32pm EST
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 54.8M | IPO Year: | 2017 |
| Target Price: | $22.17 | AVG Volume (30 days): | 144.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -10.83 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.40 - $19.56 | Next Earning Date: | 05-08-2025 |
| Revenue: | $4,262,000 | Revenue Growth: | 134.56% |
| Revenue Growth (this year): | 54.43% | Revenue Growth (next year): | 149.41% |
Stock Insider Trading Activity of Cibus Inc. (CBUS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Prante Gerhard | CBUS | Director | Feb 25 '25 | Sell | $1.92 | 1,150 | $2,208.00 | 7,707 | |
| Prante Gerhard | CBUS | Director | Feb 24 '25 | Sell | $2.07 | 1,150 | $2,380.50 | 7,707 | |
| Prante Gerhard | CBUS | Director | Feb 21 '25 | Sell | $2.20 | 1,150 | $2,530.00 | 7,707 | |
| Prante Gerhard | CBUS | Director | Feb 20 '25 | Sell | $2.35 | 1,150 | $2,702.50 | 7,707 | |
| Prante Gerhard | CBUS | Director | Feb 19 '25 | Sell | $2.58 | 1,150 | $2,967.00 | 7,707 | |
| Prante Gerhard | CBUS | Director | Feb 18 '25 | Sell | $2.52 | 2,300 | $5,796.00 | 7,707 | |
| Prante Gerhard | CBUS | Director | Feb 14 '25 | Sell | $2.60 | 1,150 | $2,990.00 | 7,707 | |
| Prante Gerhard | CBUS | Director | Feb 13 '25 | Sell | $2.53 | 1,150 | $2,909.50 | 7,707 | |
| Prante Gerhard | CBUS | Director | Feb 12 '25 | Sell | $2.45 | 1,150 | $2,817.50 | 7,707 | |
| Prante Gerhard | CBUS | Director | Feb 11 '25 | Sell | $2.48 | 1,150 | $2,852.00 | 7,707 |
Latest Cibus Inc. News
CBUS Breaking Stock News: Dive into CBUS Ticker-Specific Updates for Smart Investing
GuruFocus.com
a month ago
Cibus Inc (CBUS) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Insights
GlobeNewswire
a month ago
Cibus Reports Fourth Quarter Financial Results and Provides Business Update
GlobeNewswire
a month ago
Cibus Welcomes the European Union’s Progress as Legislation for New Genomic Techniques to Boost Innovation and Sustainability Moves Forward
GlobeNewswire
a month ago
Cibus to Report Fourth Quarter 2024 Financial Results on March 20, 2025 After the Market Close and Host Conference Call
GlobeNewswire
2 months ago
Cibus’ Achieves Another Milestone for a Durable White Mold (Sclerotinia) Resistance Trait in Canola
GlobeNewswire
2 months ago
Cibus Announces Leadership Change and CEO Succession Plan
GlobeNewswire
2 months ago
Cibus Announces Important Update to Rice Gene Editing Conversion Rates
GlobeNewswire
3 months ago
Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer
Compare CBUS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CBUS Cibus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.